### In vitro / physico-chemical Data <a id="invitro-and-physico-chemical-data"></a>

A literature search was performed to collect available information on physicochemical properties of Warfarin . The obtained information from literature is summarized in the table below. 

**Physicochemical and binding properties**

| **Parameter** | **Unit** | **Value** | **Source** | **Description** |
|:--------------|:---------|----------:|:-----------|:----------------|
| MW            | g/mol    | 308.33    | 	[Drugbank](#main-references)          | Molecular weight |
| pK<sub>a</sub> |         | 5.03 (acid) |  | Acid dissociation constant within literature range 5.03-5.1 [Bi 2018](#main-references),[Stella 1984](#main-references) |
| Solubility     | mg/L     | 17 (at pH 7) | [Drugbank](#main-references) | Aqueous solubility |
| fu<sub>plasma</sub> |   | 0.009     |[Takahashi 2003](#main-references)| Fraction unbound in plasma (albumin binding) |
| LogP          |         | 3.46      |[Avdeef 1998](#main-references)|  Liposomal membrane-water partition coefficient |
| B/P           |         | 0.55      |          | Assumed blood-to-plasma ratio (used in reduction pathway) within literature range 0.51-0.59 [Bi 2018](#main-references), [Dickinson 2007](#main-references), [Sawada 1985](#main-references), [Essential Health](#main-references) |

**S-warfarin - Metabolic and clearance parameters**

| **Pathway / Enzyme** | **Parameter** | **Unit** | **Value** | **Source / Note** |
|:---------------------|:--------------|:---------|----------:|:------------------|
| CYP2C9               | Km            | µM       | 4.4       | Experimental Km within range 3.5 to 5.54 µM [Shaik 2016](#main-references),[Rettie 1992](#main-references), [Rettie 1992](#main-references), [Yong 2009](#main-references), [Crewe 2011](#main-references)|
| CYP3A4               | Km            | µM       | 14.9      | Experimental Km within range 14 to 27 [Shaik 2016](#main-references), [Jones 2010](#main-references)  |
| Reduction to alcohols| Plasma CL  |  ml/min/kg| 0.14| Metabolism reduction mediated by aldo-keto reductases (i.e., fraction metabolized ~ 10%) [Wittkowsky 2003](#main-references)|
| Reduction to alcohols| Specific CL   |  1/min    | 0.02| Metabolism reduction mediated by aldo-keto reductases (i.e., fraction metabolized ~ 10%) [Wittkowsky 2003](#main-references)|
| Renal clearance|Plasma CL | l/h/kg|       0.07 |   Consistent with fraction excreted in urine ~ 1% [FDA 2010](#main-references) |
| Renal clearance|Specific CL| 1/min|  0.02|   Consistent with fraction excreted in urine ~ 1% [FDA 2010](#main-references) |



**R-warfarin - Metabolic and clearance parameters**

| **Pathway / Enzyme** | **Parameter** | **Unit** | **Value** | **Source / Note** |
|:---------------------|:--------------|:---------|----------:|:------------------|
| CYP1A2               | Km            | µM       | 648       | Adopted from previous PK-Sim model |
| CYP2C19              | Km            | µM       | 391       | Adopted from previous PK-Sim model |
| CYP3A4               | Km            | µM       | 586       | Adopted from previous PK-Sim model |
| Reduction to alcohols|Plasma CL |ml/h/kg |0.27|  Adopted from previous PK-Sim model
| Reduction to alcohols|Specific CL| 1/min|  0.02|  Adopted from previous PK-Sim model
| Renal clearance|Plasma CL |ml/h/kg |0.07|   Adopted from previous PK-Sim model
| Renal clearance|Specific CL| 1/min|0.02|  Adopted from previous PK-Sim model 

### Clinical Data  <a id="clinical-data"></a>

A literature search was performed to collect available clinical data on Warfarin in healthy adults.

#### Model Building S-Warfarin <a id="model-building"></a>

The following studies were used for model building (training data):

| **Dose [mg]** | **Dosing** | **PK data** |**Dataset**| **Reference** |
| --------------- | ------------------- | ----------------------- | ----------------- |----------------- |
| 15| po, sd |plasma|training|[Soon 2006](#main-references)| 
| 25| po, sd |plasma|training|[Schwartz 2008](#main-references)| 

iv = intravenous; po = oral administration; tab = tablet administration; sd = single dose; qd = once daily

#### Model Verification S- Warfarin <a id="model-verification"></a>

The following studies were used for model verification:

| **Dose [mg]** | **Dosing** | **PK data** |**Dataset**| **Reference** |
| --------------- | ------------------- | ----------------------- | ----------------- |----------------- |
| 0.375| iv, tab, fasted, sd |plasma|verification|[O'Sullivan 1993](#main-references)| 
| 7.5| po, tab, fasted with meal administration 3h post-dose, sd |plasma|verification|[Frymoyer 2010](#main-references)| 
| 10| po, tab, fasted, sd |plasma|verification|[Kim 2001](#main-references)| 
| 10| po, tab, fasted, sd |plasma|verification|[Lilja 2007](#main-references)| 
| 10| po, tab, fasted, sd |plasma|verification|[Ngo 2010](#main-references)| 
| 10| po, tab, fasted, sd |plasma|verification|[Turpeinen 2013](#main-references)| 
| 13| po, tab, fed, sd |plasma|verification|[Weber 1999](#main-references)|
| 15| po, tab, fasted, sd |plasma|verification|[Schwartz 2009](#main-references)| 
| 20| po, tab, fasted, sd |plasma|verification|[Ouellet 2006](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Almeida 2008](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Dingemanse 2013](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[He 2007](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Macha 2013](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Malhotra 2011](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Rahimy 2002](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Sanwald Ducray 2014](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Stockis 2013](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Toon 1987](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Toon 1990](#main-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Mallikaarjun 1999](#main-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Sidharta 2014](#main-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Soon 2006](#main-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Yin 2011](#main-references)| 
| 30| po, tab, fasted with meal administration 4h post-dose, sd |plasma|verification|[Liao 1996](#main-references)| 


iv = intravenous; po = oral administration; tab = tablet administration; sd = single dose; qd = once daily


#### Model Verification R- Warfarin <a id="model-verification"></a>

The following studies were used for model verification:

| **Dose [mg]** | **Dosing** | **PK data** |**Dataset**| **Reference** |
| --------------- | ------------------- | ----------------------- | ----------------- |----------------- |
| 25| po, tab, fasted, sd |plasma|verification|[Almeida 2008](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Dingemande 2013](#5-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[He 2007](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Malhotra 2011](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Rahimy 2002](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Stockis 2013](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Toon 2087](#main-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Toon 1990](#main-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Mallikaarjun 1999](#main-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Sidharta 2014](#main-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Soon 2006](#main-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Yin 2011](#main-references)|
| 25| po, tab, fasted, sd |plasma|verification|[Almeida 2008](#5-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Dingemanse 2013](#5-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[He 2007](#5-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Malhotra 2011](#5-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Rahimy 2002](#5-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Stockis 2013](#5-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Toon 1987](#5-references)| 
| 25| po, tab, fasted, sd |plasma|verification|[Toon 1990](#5-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Mallikaarjun 1999](#5-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Sidharta 2014](#5-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Soon 2006](#5-references)| 
| 25| po, tab, fed, sd |plasma|verification|[Yin 2011](#5-references)|

iv = intravenous; po = oral administration; tab = tablet administration; sd = single dose; qd = once daily
